Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Alcohol Use Disorder
NCT05520775Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Sep 2022
- Primary completion
- Apr 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in alcohol use disorder (AUD), sponsored by University of North Carolina at Chapel Hill. Started Sep 2022; status: completed.
02
Drugs
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT05520775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05520775.